璧辰（上海）医药科技有限公司 ABM THERAPEUTICS SHANGHAI COMPANY LIMITED
{{company.company_channel.channel_name}}
Media Room
{{company.company_name_local}}
{{company.company_channel.channel_name}}
Company Profile
Media Room
ABM Therapeutics' ABM-1310 Granted Fast Track Designation by the FDA Following Orphan Drug Designation 2023-09-27 00:00
ABM Therapeutics Announces First Patient Dosed in Phase I Study of ABM-1310 in patients with BRAF V600 in Relapsed and Drug Resistant Primary Malignant Brain Tumors 2023-09-02 00:00
U.S. FDA Grants Orphan Drug Designation to ABM-1310 for the Treatment of Patients with Glioblastoma Harboring BRAF V600 Mutation 2023-08-03 00:00
ABM Announces First Patient Dosed in Phase I Clinical Trial of MEK Inhibitor for Solid Tumor 2023-05-05 01:00
ABM Therapeutics Receives IND Approval in China for BRAF Inhibitor ABM-1310 2021-11-30 13:00
ABM Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial of ABM-1310 in the USA 2020-06-22 23:00
1